Literature DB >> 16441473

Validation of a 7-point Global Overall Symptom scale to measure the severity of dyspepsia symptoms in clinical trials.

S J O Veldhuyzen van Zanten1, N Chiba, D Armstrong, A N Barkun, A B R Thomson, V Mann, S Escobedo, B Chakraborty, K Nevin.   

Abstract

BACKGROUND: Currently there is no consensus on the optimal method to measure the severity of dyspepsia symptoms in clinical trials. AIM: To validate the 7-point Global Overall Symptom scale.
METHODS: The Global Overall Symptom scale uses a 7-point Likert scale ranging from 1 = no problem to 7 = a very severe problem. Validation was performed in two randomized-controlled trials (n = 1121 and 512). Construct validity: Global Overall Symptom was compared with the Quality of Life in Reflux And Dyspepsia, Gastrointestinal Symptom Rating Scale, Reflux Disease Questionnaire and 10 specific symptoms using Spearman correlation coefficients. Test-retest reliability: The Intraclass Correlation Coefficient was calculated for patients with stable dyspepsia defined by no change in Overall Treatment Effect score over two visits. Responsiveness: effect size and standardized response mean were also calculated.
RESULTS: Construct validity: Change in Global Overall Symptom score correlated significantly with Quality of Life for Reflux And Dyspepsia, Gastrointestinal Symptom Rating Scale, Reflux Disease Questionnaire and specific symptoms (all P < 0.0002). Reliability: The Intraclass Correlation Coefficient was 0.62 (n = 205) and 0.42 (n = 270). Responsiveness: There was a positive correlation between change in Global Overall Symptom and change in symptom severity. The effect size and standardized response mean were 1.1 and 2.1, respectively.
CONCLUSION: The Global Overall Symptom scale is a simple, valid outcome measure for dyspepsia treatment trials.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16441473     DOI: 10.1111/j.1365-2036.2006.02774.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  26 in total

1.  Counselling by primary care physicians may help patients with heartburn-predominant uninvestigated dyspepsia.

Authors:  Pierre Paré; Joanna Lee; Ian A Hawes
Journal:  Can J Gastroenterol       Date:  2010-03       Impact factor: 3.522

2.  Prevalence of gastroesophageal reflux disease symptoms and effects of esomeprazole on the quality of life related to reflux and dyspepsia in patients on maintenance hemodialysis.

Authors:  Tamehachi Namikoshi; Kazuhiro Harada; Hidekazu Hatta; Takehiko Tokura; Yoshiyuki Oshiro; Tetsuichi Nishizaki; Takahiro Obata; Masahiro Mori; Takaaki Fueki; Sohachi Fujimoto; Yoshisuke Haruna; Atsunori Kuwabara; Daisuke Yorimitsu; Chieko Ihoriya; Hiroyuki Kadoya; Seiji Itano; Yasuo Fujimoto; Norio Komai; Tamaki Sasaki; Naoki Kashihara
Journal:  Clin Exp Nephrol       Date:  2015-05-31       Impact factor: 2.801

3.  A one-year economic evaluation of six alternative strategies in the management of uninvestigated upper gastrointestinal symptoms in Canadian primary care.

Authors:  Alan N Barkun; Ralph Crott; Carlo A Fallone; Wendy A Kennedy; Jean Lachaine; Carey Levinton; David Armstrong; Naoki Chiba; Alan Thomson; Sander Veldhuyzen van Zanten; Paul Sinclair; Sergio Escobedo; Bijan Chakraborty; Sandra Smyth; Robert White; Helen Kalra; Krista Nevin
Journal:  Can J Gastroenterol       Date:  2010-08       Impact factor: 3.522

4.  The Ameliorating Effect of Lactobacillus gasseri OLL2716 on Functional Dyspepsia in Helicobacter pylori-Uninfected Individuals: A Randomized Controlled Study.

Authors:  Toshihiro Ohtsu; Atsushi Takagi; Naomi Uemura; Kazuhiko Inoue; Hisakuni Sekino; Akihiro Kawashima; Masayuki Uchida; Yasuhiro Koga
Journal:  Digestion       Date:  2017-07-29       Impact factor: 3.216

5.  Challenges and lessons learned from clinical pharmacogenetic implementation of multiple gene-drug pairs across ambulatory care settings.

Authors:  Emily J Cicali; Kristin Wiisanen Weitzel; Amanda R Elsey; Frank A Orlando; Michelle Vinson; Scott Mosley; D Max Smith; Richard Davis; Lori Drum; David Estores; James P Franciosi; Melanie Gross Hagen; Gabriel J Jerkins; Elvira S Mercado; Jaison Nainaparampil; Adaixa Padron; Eric I Rosenberg; Ashleigh Wright; Siegfried O Schmidt; Carol A Mathews; Larisa H Cavallari; Julie A Johnson
Journal:  Genet Med       Date:  2019-03-30       Impact factor: 8.822

6.  An Extract of Glycyrrhiza glabra (GutGard) Alleviates Symptoms of Functional Dyspepsia: A Randomized, Double-Blind, Placebo-Controlled Study.

Authors:  Kadur Ramamurthy Raveendra; Venkatappa Srinivasa; Kadur Raveendra Sushma; Joseph Joshua Allan; Krishnagouda Shankargouda Goudar; Hebbani Nagarajappa Shivaprasad; Kudiganti Venkateshwarlu; Periasamy Geetharani; Gopalakrishna Sushma; Amit Agarwal
Journal:  Evid Based Complement Alternat Med       Date:  2011-06-16       Impact factor: 2.629

7.  Safety and Effectiveness of Essential Phospholipids Paste in Patients with Non-alcoholic Fatty Liver Disease or Viral Hepatitis.

Authors:  Vladimir T Ivashkin; Igor V Maev; Chavdar S Pavlov; Marina V Mayevskaya; Aleksey A Samsonov; Lyudmila K Palgova; Kirill M Starostin
Journal:  Turk J Gastroenterol       Date:  2021-09       Impact factor: 1.555

8.  Responsiveness of measures of heartburn improvement in non-erosive reflux disease.

Authors:  Ola Junghard; Katarina Halling
Journal:  Health Qual Life Outcomes       Date:  2007-06-11       Impact factor: 3.186

9.  Efficacy of prosultiamine treatment in patients with human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: results from an open-label clinical trial.

Authors:  Tatsufumi Nakamura; Tomohiro Matsuo; Taku Fukuda; Shinji Yamato; Kentaro Yamaguchi; Ikuo Kinoshita; Toshio Matsuzaki; Yoshihiro Nishiura; Kunihiko Nagasato; Tomoko Narita-Masuda; Hideki Nakamura; Katsuya Satoh; Hitoshi Sasaki; Hideki Sakai; Atsushi Kawakami
Journal:  BMC Med       Date:  2013-08-15       Impact factor: 8.775

10.  A multicentre randomised trial to compare the efficacy of omeprazole versus rabeprazole in early symptom relief in patients with reflux esophagitis.

Authors:  Akihito Nagahara; Tsuyoshi Suzuki; Naoyoshi Nagata; Nozomu Sugai; Yoshiaki Takeuchi; Kouichi Sakurai; Masaki Miyamoto; Kazuhiko Inoue; Junichi Akiyama; Katsuhiro Mabe; Ichiro Konuma; Tomoari Kamada; Ken Haruma
Journal:  J Gastroenterol       Date:  2013-12-24       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.